NCT00032786已完成3 期
A Phase 3, International, Multicenter, Double-blind, Placebo-controlled Study of the Efficacy, Safety, and Tolerability of Intravenous Antegren (Natalizumab) in Maintaining Clinical Response and Remission in Subjects With Crohn's Disease
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- Biogen
研究概览
简要总结
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderate to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female patients at least 18 years of age who have at least a six-month history of Crohn's disease and who are currently experiencing moderate to severely active Crohn's disease. Women must not be breastfeeding or pregnant, and must not become pregnant during this study. Patient enrollment requires previous participation in study AN100226-CD301 (please refer to the clinical trial listing for CD301).
排除标准
- 未提供
研究者
相似试验
已完成
3 期
Safety and Efficacy of Natalizumab in the Treatment of Crohn's DiseaseCrohn's DiseaseNCT00032799Biogen905
终止
2 期
Natalizumab in the Treatment of Rheumatoid Arthritis in Subjects Receiving MethotrexateRheumatoid ArthritisNCT00083759Biogen299
已完成
2 期
Safety and Efficacy of Natalizumab in Combination With Remicade in the Treatment of Crohn's DiseaseCrohn's DiseaseNCT00055536Biogen60
已完成
3 期
A Clinical Trial of Natalizumab in Individuals With Moderately to Severely Active Crohn's DiseaseCrohn's DiseaseNCT00078611Biogen462
已完成
3 期
Safety and Efficacy of Natalizumab in the Treatment of Multiple SclerosisMultiple Sclerosis, Relapsing-RemittingNCT00027300Biogen900